P-gp-IN-35 

P-gp-IN-35 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-35 exhibits cytotoxicity against sensitive breast cancer and colorectal cancer cells, and can reverse multidrug resistance in breast cancer cells with P-gp overexpression. P-gp-IN-35 can be used in research related to multidrug-resistant breast cancer and colon cancer^[1].

P-gp-IN-35 (Compound 4d) (24 h) potently inhibits the proliferation of MCF-7, Caco-2 and multidrug-resistant MCF-7/ADR cancer cells with IC₅₀ values of 8.14, 9.04 and 19.32 μM, respectively; compared with normal HFL-1 and WI-38 lung fibroblasts, this compound exhibits selective toxicity toward cancer cells^[1].
P-gp-IN-35 (1-100 μM; 48 h) downregulates the expression of P-glycoprotein in MCF-7/ADR cells in a concentration-dependent manner, with an inhibition rate of 61.27% at 100 μM. It also reverses P-gp-mediated multidrug resistance, with an IC₅₀ of 15.09 μM^[1].
P-gp-IN-35 inhibits the activity of P-glycoprotein efflux pump in MCF-7/ADR cells, with an IC₅₀ value of 47.08 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

364.78

C₂₀H₁₃ClN₂O₃

1887151-21-4

NC(O1)=C(C#N)C(C2=CC=CC(Cl)=C2)C3=C1C4=CC(C)=CC=C4OC3=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Helal MH, et al. Targeting P-glycoprotein with novel halogenated 4H-pyran-coumarin hybrids: a combined experimental, computational approach to tumor-sensitive and -resistant (breast) cancer cell lines. J Biomol Struct Dyn. Published online December 26, 2025.  [Content Brief]